Avience Biomedicals shares surged on their market debut Thursday, listing at ₹395.20 on the NSE SME platform.
The opening price represents a 90% premium over the IPO issue price of ₹208, signaling strong initial demand from retail and institutional investors alike.
The sharp repricing follows a bidding period that closed Monday, during which the SME IPO attracted a staggering 385 times oversubscription.
Share allotment was finalized on Tuesday, June 23, setting the stage for the listing.
The magnitude of the premium reflects the intense competition for limited shares in the small-cap segment.
This debut aligns with a broader trend of heightened investor appetite for SME IPOs in India.